Log in to search using one of your social media accounts:

 

Effect of memantine on serum levels of neuron-specific enolase and on the Glasgow Coma Scale in patients with moderate traumatic brain injury - Mokhtari M, Nayeb-Aghaei H, Kouchek M, Miri MM, Goharani R, Amoozandeh A, Akhavan Salamat S, Sistanizad M.
We examined the effect of memantin... (Source: SafetyLit)
Source: SafetyLit - July 24, 2017 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Alzheimer's drug may help traumatic brain injury patients
Researchers have found that the drug, memantine, used to treat dementia associated with Alzheimer's disease may help traumatic brain injury patients as well. (Source: Health News - UPI.com)
Source: Health News - UPI.com - July 21, 2017 Category: Consumer Health News Source Type: news

Drug combined with care program better at reducing Alzheimer's symptoms than drug alone
(NYU Langone Medical Center / New York University School of Medicine) Combining a specific care management program with a commonly-prescribed drug for Alzheimer's, memantine, multiplies the medication's ability to improve daily function by about 7.5 times, stalling some of the disease's most damaging effects, according to new research from NYU Langone Medical Center. With no significant new drug for Alzheimer's having been approved since 2003, the study authors say the time has come for the field to pay more attention to methods that can improve the impact of existing drugs. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 16, 2017 Category: International Medicine & Public Health Source Type: news

Zydus Cadila gets USFDA nod to market anti-dementia tablets
"Zydus Cadila has received final approval from the USFDA to market Memantine Hydrochloride tablets USP, 5mg and 10mg," Cadila Healthcare said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 12, 2017 Category: Pharmaceuticals Source Type: news

Attorneys'' Falsehoods' Cause Dismissal Of Namenda Lawsuit; Appeal Follows
Judge F. Dennis Saylor IV dismissed the case on April 28, ruling attorneys at Milberg LLP who represented a whistleblower participated in “an elaborate series of falsehoods, misrepresentation, and deceptive conduct. " A month later, those attorneys filed their notice of appeal. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 5, 2017 Category: Pharmaceuticals Authors: Legal Newsline, Contributor Source Type: news

Namzaric (Memantine Hydrochloride Extended-release and Donepezil Hydrochloride Capsules) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 5, 2017 Category: Drugs & Pharmacology Source Type: news

The effect of an interactive cycling training on cognitive functioning in older adults with mild dementia: study protocol for a randomized controlled trial - Karssemeijer EGA, Bossers WJR, Aaronson JA, Kessels RPC, Rikkert MGMO.
BACKGROUND: To date there is no cure or an effective disease-modifying drug to treat dementia. Available acetylcholine-esterase inhibiting drugs or memantine only produce small benefits on cognitive and behavioural functioning and their clinical relevance ... (Source: SafetyLit)
Source: SafetyLit - June 15, 2017 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Strides Shasun gets USFDA nod for dementia drug
Quoting IMS sales data, Strides Shasun said the US market for memantine hydrochloride tablets USP, 5mg and 10 mg is approximately USD 60 million. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 24, 2017 Category: Pharmaceuticals Source Type: news

Memantine improves outcomes after repetitive traumatic brain injury - Mei Z, Qiu J, Alcon S, Hashim J, Rotenberg A, Sun Y, Meehan WP, Mannix R.
Repetitive mild traumatic brain injury (rmTBI; e.g., sports concussions) is common and results in significant cognitive impairment. Targeted therapies for rmTBI are lacking, though evidence from other injury models indicates that targeting N-methyl-d-aspar... (Source: SafetyLit)
Source: SafetyLit - April 26, 2017 Category: Global & Universal Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Namenda XR (Memantine Hydrochloride Extended Release Capsules) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 17, 2017 Category: Drugs & Pharmacology Source Type: news

Among antidementia drugs, memantine is associated with the highest risk of pneumonia
A recent study from the University of Eastern Finland shows that among users of antidementia drugs, persons using memantine have the highest risk of pneumonia. The use of rivastigmine patches is associated with an increased risk as well. The study found that persons using donepezil or galantamine had the lowest risk of pneumonia. (Source: World Pharma News)
Source: World Pharma News - November 25, 2016 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Another Failure In Search For Treatment To Slow Alzheimer ’ s
INDIANAPOLIS (AP) — An experimental treatment for Alzheimer’s failed again in a widely anticipated study, disappointing many who had hoped Eli Lilly had finally found a way to slow the progression of the mind-robbing disease. The drug did not work better than a placebo treatment in a study of 2,100 people with mild Alzheimer’s, the company announced Wednesday. “We’re incredibly saddened by the news,” said Maria Carrillo, chief science officer of the Alzheimer’s Association, who was not involved in Lilly’s research. “There was a lot of hope for this avenue, this approach...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - November 23, 2016 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health Local News Alzheimer's Disease Solanezumab Source Type: news

Among antidementia drugs, memantine is associated with the highest risk of pneumonia
Among users of antidementia drugs, persons using memantine have the highest risk of pneumonia, new research shows. The use of rivastigmine patches is associated with an increased risk as well, say researchers. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 21, 2016 Category: Science Source Type: news

FDA approves Lannett's generic dementia drug
The Food and Drug Administration has approved Lannett Co. Inc. ’s application to market memantine hydrochloride tablets for the treatment of dementia. The product is the generic equivalent of Namenda, a medicine developed by Forest Laboratories to treat moderate-to-severe dementia in patients, including those suffering from Alzheimer’s disease. Dr. Reddy’ s Laboratories and Mylan were the first to introduce generic versions of Namenda last year. Teva Pharmaceutical Industries (NYSE: TEVA),… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 14, 2016 Category: Biotechnology Authors: John George Source Type: news

Allergan Issues Statement on Namenda XR Patent Litigation Following Announcement of ANDA Approvals
DUBLIN, Sept. 29, 2016 -- (Healthcare Sales & Marketing Network) -- Allergan plc (AGN), today issued the following statement regarding ongoing litigation on patents related to NAMENDA XR® (memantine hydrochloride) extended release capsules following a... Biopharmaceuticals, Generics, FDA, Litigation Allergan, NAMENDA, memantine, Lupin Pharmaceuticals (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 29, 2016 Category: Pharmaceuticals Source Type: news

Treatment of Alzheimer ’ s Disease
There is no cure for Alzheimer’s disease and no way to slow the progression of the disease. For some people in the early or middle stages of Alzheimer’s disease, medication such as tacrine (Cognex) may alleviate some cognitive symptoms. Donepezil (Aricept), rivastigmine (Exelon), and galantamine (Reminyl) may keep some symptoms from becoming worse for a limited time. A fifth drug, memantine (Namenda), has also been approved for use in the United States. Combining memantine with other Alzheimer’s disease drugs may be more effective than any single therapy. One controlled clinical trial found that patients...
Source: Psych Central - August 17, 2016 Category: Psychiatry Authors: Jane Framingham, Ph.D. Tags: Alzheimer's Medications Memory and Perception Alzheimer's treatment Cognex donepezil Drug Exelon galanta Namenda Reminyl rivastigmine tacrine treatment of alzheimers Source Type: news

Clinical Trials For New Alzheimer's Medication
Inside Science News Servicenoted on April 16, 2016 that "Alzheimer's is a graveyard for expensive drug tests. One study showed that between 2000 and 2012, 244 compounds were tested in 413 clinical trials. Only one was approved for use, a failure rate of 99.6 percent." The one medication that was approved since the year 2000, Namzeric, is a medication that combines two previously FDA-approved medications, donepezil and memantine, into one capsule. But neither donepezil nor memantine are medications that effectively treat or significantly improve the lives of most people who take them. Even the third sentence on ...
Source: Healthy Living - The Huffington Post - July 19, 2016 Category: Consumer Health News Source Type: news

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease
This guidance updates and replaces NICE technology appraisal guidance 111 issued in November 2006 (amended September 2007, August 2009). The review and re-appraisal of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease has resulted in a change in the guidance. Specifically: donepezil, galantamine and rivastigmine are now recommended as options for managing mild as well as moderate Alzheimer's disease, and memantine is now recommended as an option for managing moderate Alzheimer's disease for people who cannot take AChE inhibitors, and as an option for managing severe Alzhei...
Source: Current Awareness Service for Health (CASH) - July 12, 2016 Category: Consumer Health News Source Type: news

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease
This guidance updates and replaces NICE technology appraisal guidance 111 issued in November 2006 (amended September 2007, August 2009). The review and re-appraisal of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease has resulted in a change in the guidance. Specifically: donepezil, galantamine and rivastigmine are now recommended as options for managing mild as well as moderate Alzheimer's disease, and memantine is now recommended as an option for managing moderate Alzheimer's disease for people who cannot take AChE inhibitors, and as an option for managing severe Alzheimer'...
Source: Current Awareness Service for Health (CASH) - July 12, 2016 Category: Consumer Health News Source Type: news

memantine, Namenda, Namenda XR
Title: memantine, Namenda, Namenda XRCategory: MedicationsCreated: 11/3/2003 12:00:00 AMLast Editorial Review: 6/20/2016 12:00:00 AM (Source: MedicineNet Alzheimer)
Source: MedicineNet Alzheimer - June 20, 2016 Category: Geriatrics Source Type: news

Characteristics of pediatric exposures to antidementia drugs reported to a poison control system - Thornton SL, Pchelnikova JL, Cantrell FL.
OBJECTIVE: To characterize pediatric exposures to the antidementia drugs donepezil, memantine, rivastigmine, and galantamine by reviewing a poison control system's database. STUDY DESIGN: A retrospective review of a statewide poison control system's databa... (Source: SafetyLit)
Source: SafetyLit - March 11, 2016 Category: Global & Universal Tags: Age: Infants and Children Source Type: news

Memantine Hydrochloride (Namenda) Unit Dose XR Capsules (New - Discontinuation)
Updated Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - February 17, 2016 Category: Drugs & Pharmacology Source Type: news

Memantine Hydrochloride (Namenda) XR Capsules (Updated - Resolved)
Updated Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - February 3, 2016 Category: Drugs & Pharmacology Source Type: news

Pfizer-Allergan deal a prelude to splitting company
(Reuters) — A Pfizer (NYSE:PFE) merger with Ireland-based Allergan (NYSE: AGN), in addition to providing tax benefits, would bolster the U.S. drugmaker’s growth prospects should it decide to sell or spin off its portfolio of products that have gone off patent. Many Wall Street analysts believe Pfizer will decide to split late next year, after compiling 3 years of financial data treating its “established products” division, which sells generic medicines, and its “innovative” patent-protected medicines unit, as if they were separate companies. Such a split would dramatically boos...
Source: Mass Device - November 6, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Mergers & Acquisitions Pharmaceuticals Allergan Inc. Pfizer Inc. Source Type: news

Cheap Alzheimer's drug 'may help keep people out of care homes'
Conclusion This randomised controlled trial assessed the impact of continuing or discontinuing the Alzheimer's drug donepezil on the chances of nursing home admission in people with moderate to severe Alzheimer's. The study examined discontinuing or continuing donepezil, either alone or in combination with memantine, or switching to memantine alone. Memantine is currently licensed for the treatment of moderate to severe Alzheimer's, while donepezil is only licensed for mild to moderate forms of the disease. In this trial, people had already been taking donepezil for three to six months or more. These drugs are only given...
Source: NHS News Feed - October 27, 2015 Category: Consumer Health News Tags: Medication Mental health Neurology Older people Source Type: news

Aurobindo Pharma gets US FDA nod for Alzheimer's drug Memantine Hydrochloride
Aurobindo Pharma said it has received final approval from the US FDA to manufacture and market Memantine Hydrochloride used in treatment of Alzheimer's. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 15, 2015 Category: Pharmaceuticals Source Type: news

Dr Reddy's launches generic dementia treatment tablets in US
Dr Reddy's Laboratories has launched in the US market the generic Memantine hydrochloride tablets used for treatment of dementia of the Alzheimer's type. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 13, 2015 Category: Pharmaceuticals Source Type: news

Dr Reddy's Laboratories launches generic dementia treatment tablets in US
Drug firm Dr Reddy's Laboratories has launched in the US market the generic Memantine hydrochloride tablets used for treatment of dementia. (Source: The Economic Times)
Source: The Economic Times - July 13, 2015 Category: Consumer Health News Source Type: news

Dementia Drug May Help Improve ADHD SymptomsDementia Drug May Help Improve ADHD Symptoms
Memantine, a drug used for the treatment of dementia, may help improve impaired executive function in adults with ADHD when used with standard stimulant therapy. Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - June 17, 2015 Category: Psychiatry Tags: Psychiatry News Source Type: news

Court Says No to Actavis Plan to Thwart Namenda Generics
A U.S. Court of Appeals has upheld a December decision declaring that Ireland-based Actavis must keep Namenda, it's dementia drug, on the market. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - May 28, 2015 Category: Pharmaceuticals Source Type: news

Business Briefing: Court Bars Removal of Cheaper Alzheimer’s Drug
A federal appeals court in New York ruled on Friday that Actavis cannot withdraw its top-selling Alzheimer’s disease drug from the market in favor of a more expensive extended-release version. (Source: NYT Health)
Source: NYT Health - May 22, 2015 Category: Consumer Health News Authors: REUTERS Tags: Alzheimer's Disease Actavis PLC ACT NYSE Drugs (Pharmaceuticals) Suits and Litigation (Civil) Namenda XR Antitrust Laws and Competition Issues New York State Namenda IR Source Type: news

Battle Over Namenda Swap Has Big Stakes for Drugmakers, Consumers
(MedPage Today) -- At issue: an aggressive, some say unethical and illegal, drug sales tactic. (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - March 20, 2015 Category: Psychiatry Source Type: news

Namzaric (Memantine/Donepezil) for the Treatment of Alzheimer's Disease
Namzaric (memantine/donepezil) is the first fixed-dose combination drug approved for the treatment of moderate and severe Alzheimer's disease in the US. (Source: Drug Development Technology)
Source: Drug Development Technology - February 17, 2015 Category: Pharmaceuticals Source Type: news

Namzaric (Memantine Hydrochloride Extended-release and Donepezil Hydrochloride Capsules) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 2, 2015 Category: Drugs & Pharmacology Source Type: news

Judge delivers blow to maker of Alzheimer's drug
The maker of the Alzheimer's drug Namenda announced it would stop selling the drug and was moving patients to a newer version called Namenda XR. But New York's attorney general filed a lawsuit, saying the practice blocked competition and was illegal. Dr. Jon LaPook has the latest developments. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - January 1, 2015 Category: Consumer Health News Source Type: news

Judge makes ruling in Alzheimer's drug case
A lawsuit claimed the makers of Namenda were trying to avoid competition from cheaper generic drugs (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - January 1, 2015 Category: Consumer Health News Source Type: news

FDA OKs Namzaric Combo Pill for Alzheimer's DiseaseFDA OKs Namzaric Combo Pill for Alzheimer's Disease
The memantine/donepezil combination offers a once-daily fixed-dose combination of two treatments often prescribed together in one capsule. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 27, 2014 Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news

Actavis and Adamas Announce FDA Approval of Namzaric(TM), a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride
Indicated for Treatment of Moderate to Severe Alzheimer's Disease DUBLIN and EMERYVILLE, Calif., Dec. 24, 2014 -- (Healthcare Sales & Marketing Network) -- Actavis plc (ACT) and Adamas Pharmaceuticals Inc. (ADMS) today announced that the U.S. Food and ... Biopharmaceuticals, Neurology, FDAActavis , Adamas Pharmaceuticals, Namzaric, Alzheimer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 24, 2014 Category: Pharmaceuticals Source Type: news

Actavis' Stance On Namenda Is Harming Pharma's Image
Discontinuation of Namenda in order to boost sales of the XR version reinforces all of the bad views that people have of the pharmaceutical industry and provides great fodder for its critics. Actavis has joined the “Big Pharma” club. It would be nice if it became part of the solution to Big Pharma’s image woes, rather than adding to the problem. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - December 17, 2014 Category: Pharmaceuticals Authors: John LaMattina Source Type: news

Study finds Alzheimer's drug may reduce the urge to binge eat
(Boston University Medical Center) The Alzheimer's drug memantine may perform double-duty helping binge eaters control their compulsion. Researchers have demonstrated that memantine, a neuroprotective drug, may reduce the addictive and impulsive behavior associated with binge eating. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - November 13, 2014 Category: Global & Universal Source Type: news

Fibromyalgia: Memantine Reduced Pain in Small, Blinded TrialFibromyalgia: Memantine Reduced Pain in Small, Blinded Trial
Memantine, an agent primarily used to treat patients with Parkinson's or Alzheimer's disease, may provide pain relief and improve the quality of life of patients with fibromyalgia. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 8, 2014 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Forest Laboratories' Namenda Is Focus of Lawsuit
The state attorney general said Actavis’s plan to stop selling an older tablet in favor of a newer one was an attempt to maintain a monopoly. (Source: NYT Health)
Source: NYT Health - September 15, 2014 Category: Consumer Health News Authors: By ANDREW POLLACK Tags: Forest Laboratories Inc FRX NYSE Drugs (Pharmaceuticals) Suits and Litigation (Civil) Warner Chilcott Ltd WCRX NASDAQ Antitrust Laws and Competition Issues New York State Walgreen Company WAG NYSE Actavis Abbott Laboratories ABT NYSE Gen Source Type: news

Alzheimer's Drug May Enhance Stroke Recovery Alzheimer's Drug May Enhance Stroke Recovery
Memantine may improve stroke outcomes in a non-neuroprotective way, preliminary research suggests. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 5, 2014 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Memantine Discussed in New Comprehensive Patent Search Report by Ark...
New comprehensive report “Memantine - Comprehensive patent search” elaborated by Ark Patent Intelligence is now available at MarketPublishers.com.(PRWeb July 24, 2014)Read the full story at http://www.prweb.com/releases/2014/07/prweb12045121.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 25, 2014 Category: Pharmaceuticals Source Type: news

Stroke Rounds: Dementia Drug for Stroke Recovery?
(MedPage Today) -- The Alzheimer's disease drug memantine (Namenda) might be worth a look for improving recovery from stroke, a mouse-model study suggested. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - July 22, 2014 Category: Cardiology Source Type: news

Jubilant Life Sciences gets USFDA nod for generic drugs
"We expect to launch this product post patent expiry in 2015. The total market size for Namenda as per IMS is $1.85 billion per annum," the company said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 25, 2014 Category: Pharmaceuticals Source Type: news

Cognitive Enhancers for Mild Cognitive ImpairmentCognitive Enhancers for Mild Cognitive Impairment
What does the research say about using cholinesterase inhibitors or memantine to improve cognition or function? Medscape Psychiatry (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - April 8, 2014 Category: Psychiatry Tags: Psychiatry Commentary Source Type: news

Memory and mood during MDMA intoxication, with and without memantine pretreatment - de Sousa Fernandes Perna EB, Theunissen EL, Kuypers KP, Heckman P, de la Torre R, Farré M, Ramaekers JG.
Previous studies have shown that single doses of MDMA can affect mood and impair memory in humans. The neuropharmacological mechanisms involved in MDMA-induced memory impairment are not clear. Memantine, an NMDA and alpha 7 nicotinic acetylcholine (ACh) re... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - April 4, 2014 Category: Global & Universal Tags: Alcohol and Other Drugs Source Type: news

Memantine Discontinuation Rates Underestimated in Research?Memantine Discontinuation Rates Underestimated in Research?
Randomized clinical trials may underestimate the rate of memantine discontinuation and dose reductions in dementia patients. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 6, 2014 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Forest Laboratories submits NDA to FDA for combination drug to treat Alzheimer's disease
US-based Forest Laboratories has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for a fixed-dose combination (FDC) of memantine HCl extended release (ER) and donepezil HCl to treat moderate to severe Alzheimer's t… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 6, 2014 Category: Pharmaceuticals Source Type: news